Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFFI TACHDJIAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1447376454
CMS profile
201171
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$567,705.90

727 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 15; records 101–150 of 727 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFFI TACHDJIAN

NPI 1447376454 · CMS profile ID 201171

Allopathic & Osteopathic Physicians / Allergy & Immunology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 15; records 101–150 of 727 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447376454?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFFI TACHDJIAN, NPI 1447376454, CMS profile ID 201171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 15; records 101–150 of 727 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447376454?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RAFFI TACHDJIAN, NPI 1447376454, CMS profile ID 201171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 15; records 101–150 of 727 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447376454?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RAFFI TACHDJIAN, NPI 1447376454, CMS profile ID 201171, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 15; records 101–150 of 727 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447376454?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

727 matching records · $567,705.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 727 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 727.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $10.1210/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029673 CMS
Pharming Healthcare, Inc. $89.0010/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029351869 CMS
Regeneron Healthcare Solutions, Inc. $26.9510/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482321 CMS
GENZYME CORPORATION $25.0010/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049951329 CMS
Regeneron Healthcare Solutions, Inc. $24.3710/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482311 CMS
Pharming Healthcare, Inc. $18.8210/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029351863 CMS
Pharming Healthcare, Inc. $39.3010/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029351851 CMS
Pharming Healthcare, Inc. $84.8610/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029351857 CMS
Regeneron Healthcare Solutions, Inc. $224.9510/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482303 CMS
Grifols USA, LLC $676.3210/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762553 CMS
Grifols USA, LLC $180.0010/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762559 CMS
Grifols USA, LLC $429.0510/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762565 CMS
Grifols USA, LLC $77.3910/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762571 CMS
Grifols USA, LLC $26.8510/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762577 CMS
Grifols USA, LLC $17.0310/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762583 CMS
Grifols USA, LLC $25.0010/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762589 CMS
Grifols USA, LLC $25.0010/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762595 CMS
Grifols USA, LLC $29.9910/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762601 CMS
Grifols USA, LLC $50.0010/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762607 CMS
Grifols USA, LLC $4,500.0010/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011766769 CMS
CSL Behring $114.3010/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029467 CMS
CSL Behring $784.4010/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029475 CMS
CSL Behring $215.4610/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029485 CMS
Regeneron Healthcare Solutions, Inc. $6,227.0010/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482297 CMS
CSL Behring $110.0810/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029459 CMS
GENZYME CORPORATION $2,076.0010/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049951333 CMS
BioCryst US Sales Co., LLC $9.6310/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560035 CMS
BioCryst US Sales Co., LLC $152.5510/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560269 CMS
BioCryst US Sales Co., LLC $29.3910/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560311 CMS
GENZYME CORPORATION $2,817.0010/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049951397 CMS
GENZYME CORPORATION $86.5010/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049951401 CMS
GENZYME CORPORATION $15.7210/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049951405 CMS
Pharming Healthcare, Inc. $5,400.0010/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029351845 CMS
BioCryst US Sales Co., LLC $6,555.0010/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560015 CMS
BioCryst US Sales Co., LLC $83.0010/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560019 CMS
BioCryst US Sales Co., LLC $9.6310/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560023 CMS
BioCryst US Sales Co., LLC $8.4810/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560027 CMS
BioCryst US Sales Co., LLC $34.9810/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560031 CMS
BioCryst US Sales Co., LLC $153.2810/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560039 CMS
BioCryst US Sales Co., LLC $412.2110/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560043 CMS
BioCryst US Sales Co., LLC $148.0010/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560047 CMS
BioCryst US Sales Co., LLC $249.8010/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560261 CMS
BioCryst US Sales Co., LLC $88.3510/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560265 CMS
Regeneron Healthcare Solutions, Inc. $294.6410/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482289 CMS
CSL Behring $570.2310/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043028791 CMS
CSL Behring $7.5510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029665 CMS
Regeneron Healthcare Solutions, Inc. $517.8010/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999482281 CMS
CSL Behring $7.7610/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029409 CMS
CSL Behring $10.0210/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029415 CMS
CSL Behring $5.0010/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043029423 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $499,783.61 575
PY2020 $181,234.73 209
PY2021 $235,732.15 248
PY2022 $429,618.26 485
PY2023 $567,705.90 727
PY2024 $648,552.69 656
PY2025 $1,092,012.36 830

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $19,962.00 10
PY2025 Principal investigator $37,409.86 11
PY2024 Recipient $42,059.00 33
PY2024 Principal investigator $15,399.00 1
PY2023 Principal investigator $8,350.20 9
PY2022 Principal investigator $133,980.25 49
PY2021 Recipient $34,328.80 8
PY2021 Principal investigator $136,221.14 27
PY2020 Principal investigator $51,592.00 27
PY2019 Principal investigator $206,057.66 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,094.18 12/10/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN MD INC
IS744CS7 No dispute reported 06/30/2026 1246791340
Principal investigator 1 Ionis Pharmaceuticals, Inc. $7,164.18 08/07/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN MD INC
IS744CS7 No dispute reported 06/30/2026 1246786330
Recipient CSL Behring $1,365.00 07/09/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,153.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,868.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,000.00 06/11/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184205821
Principal investigator 1 GlaxoSmithKline, LLC. $2,799.00 06/06/2025 Non-covered Recipient Entity
RAFFI TACHDJIAN MD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192170621
Recipient CSL Behring $200.00 06/02/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669968
Recipient CSL Behring $250.00 06/02/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669970
Recipient CSL Behring $500.00 06/02/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669972
Recipient CSL Behring $2,247.00 05/30/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669966
Recipient CSL Behring $13,000.00 05/28/2025 Covered Recipient Physician A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252669956
Principal investigator 1 CSL Behring $203.50 05/28/2025 Non-covered Recipient Entity
AIRE Medical of Los Angeles
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673584
Principal investigator 1 CSL Behring $2,503.00 03/26/2025 Non-covered Recipient Entity
AIRE Medical of Los Angeles
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673582
Recipient CSL Behring $50.00 03/05/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669958
Recipient CSL Behring $250.00 03/05/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669960
Recipient CSL Behring $600.00 03/05/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669962
Recipient CSL Behring $1,500.00 03/05/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252669964